Agarwal Puneet, Agarwal Renu, Iezhitsa Igor
School of Medicine, International Medical University, Wilayah Persekutuan 57000, Malaysia.
Int J Ophthalmol. 2025 Jun 18;18(6):1131-1145. doi: 10.18240/ijo.2025.06.21. eCollection 2025.
Glaucoma, a degenerative optic neuropathy, causes retinal ganglion cell (RGC) apoptosis and irreversible vision loss. Current therapies often fail to stop disease progression despite lowering intraocular pressure, the main risk factor. Thus, neuroprotective strategies have gained interest. We performed a bibliometric analysis to determine global publishing trends and relationships among prolific authors, publications, institutions, funding agencies, and journals. We also analyzed author keywords to identify research hotspots in glaucoma neuroprotection. Further, based on keyword analysis, we reviewed most recent literature to understand mechanistic pathways underlying glaucoma-related pathophysiological responses leading to RGC loss. Bibliographic data were sourced from Scopus. Basic bibliographic features were characterized using Scopus's functions. VOSviewer was used for mapping and visualizing bibliometric networks. The analysis included trends in publications since 2000, the most prolific countries, institutions, authors, and the strength of their linkages. A significant increase in publication output over the past two decades was noted. The United States leads in funding support, research output, and citation links, followed by China and the UK. Among the top 10 most cited authors, three are from Japanese institutions. Keyword analysis shows a focus on molecular targets related to ischemia, excitotoxicity, inflammation, and oxidative stress, with fewer emerging drug candidates and limited clinical trials. Based on the most recent literature, emerging molecular targets underlying these key pathophysiological mechanisms are summarized. In conclusion, while pathophysiology and molecular mechanisms are the current focus, there is not much progress in developing new drug candidates and conducting clinical trials.
青光眼是一种退行性视神经病变,可导致视网膜神经节细胞(RGC)凋亡和不可逆转的视力丧失。尽管降低了主要危险因素眼压,但目前的治疗方法往往无法阻止疾病进展。因此,神经保护策略受到了关注。我们进行了一项文献计量分析,以确定全球出版趋势以及多产作者、出版物、机构、资助机构和期刊之间的关系。我们还分析了作者关键词,以确定青光眼神经保护的研究热点。此外,基于关键词分析,我们回顾了最新文献,以了解导致RGC丧失的青光眼相关病理生理反应的潜在机制途径。文献数据来自Scopus。使用Scopus的功能对基本文献特征进行了表征。VOSviewer用于绘制和可视化文献计量网络。分析包括2000年以来的出版物趋势、最多产的国家、机构、作者及其联系强度。注意到过去二十年出版物数量显著增加。美国在资金支持、研究产出和引用链接方面领先,其次是中国和英国。在被引用次数最多的前10位作者中,有三位来自日本机构。关键词分析表明,研究重点是与缺血、兴奋性毒性、炎症和氧化应激相关的分子靶点,新出现的候选药物较少,临床试验有限。基于最新文献,总结了这些关键病理生理机制背后新出现的分子靶点。总之,虽然病理生理学和分子机制是目前的重点,但在开发新的候选药物和进行临床试验方面进展不大。